You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLurasidone
Accession NumberDB08815
TypeSmall Molecule
GroupsApproved
DescriptionLurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. (Wikipedia)
Structure
Thumb
Synonyms
Lurasidona
Lurasidonum
External Identifiers
  • SM-13496
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LatudaTablet80 mgOralSunovion Pharmaceuticals Canada Inc2012-09-05Not applicableCanada
LatudaTablet, film coated20 mg/1OralSunovion Pharmaceuticals Inc.2011-12-07Not applicableUs
LatudaTablet, film coated120 mg/1OralSunovion Pharmaceuticals Inc.2012-04-26Not applicableUs
LatudaTablet120 mgOralSunovion Pharmaceuticals Canada Inc2012-09-06Not applicableCanada
LatudaTablet, film coated40 mg/1OralSunovion Pharmaceuticals Inc.2010-10-28Not applicableUs
LatudaTablet, film coated40 mg/1OralAvera Mc Kennan Hospital2015-03-02Not applicableUs
LatudaTablet60 mgOralSunovion Pharmaceuticals Canada Inc2014-03-14Not applicableCanada
LatudaTablet, film coated60 mg/1OralSunovion Pharmaceuticals Inc.2013-07-12Not applicableUs
LatudaTablet40 mgOralSunovion Pharmaceuticals Canada Inc2012-09-06Not applicableCanada
LatudaTablet20 mgOralSunovion Pharmaceuticals Canada Inc2014-04-09Not applicableCanada
LatudaTablet, film coated80 mg/1OralSunovion Pharmaceuticals Inc.2010-10-28Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Lurasidone Hydrochloride
Thumb
  • InChI Key: NEKCRUIRPWNMLK-SCIYSFAVSA-N
  • Monoisotopic Mass: 528.232574845
  • Average Mass: 529.137
DBSALT000113
Categories
UNII22IC88528T
CAS number367514-87-2
WeightAverage: 492.676
Monoisotopic: 492.255897106
Chemical FormulaC28H36N4O2S
InChI KeyPQXKDMSYBGKCJA-CVTJIBDQSA-N
InChI
InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1
IUPAC Name
(1R,2S,6R,7S)-4-{[(1R,2R)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}-4-azatricyclo[5.2.1.0²,⁶]decane-3,5-dione
SMILES
O=C1[[email protected]]2[C@@H]3CC[C@@H](C3)[[email protected]]2C(=O)N1C[C@@H]1CCCC[[email protected]]1CN1CCN(CC1)C1=NSC2=CC=CC=C12
Pharmacology
IndicationTreatment of schizophrenia.
Structured Indications
PharmacodynamicsLurasidone is a benzothiazol derivative that is an antagonist and binds with high affinity to Dopamine-2 (D2) (Ki = 0.994 nM), 5-HT2A (Ki = 0.47 nM) receptors, and 5-HT7 receptors (Ki = 0.495 nM). It also binds with moderate affinity to alpha-2C adrenergic receptors (Ki = 10.8 nM) and is a partial agonist at 5-HT1A receptors (Ki = 6.38 nM). Its actions on histaminergic and muscarinic receptors are negligible.
Mechanism of actionLurasidone is an atypical antipsychotic that is a D2 and 5-HT2A (mixed serotonin and dopamine activity) to improve cognition. It is thought that antagonism of serotonin receptors can improve negative symptoms of psychoses and reduce the extrapyramidal side effects that are often associated with typical antipsychotics.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
5-hydroxytryptamine receptor 7Proteinunknown
antagonist
HumanP34969 details
5-hydroxytryptamine receptor 1AProteinunknown
antagonist
HumanP08908 details
Alpha-2C adrenergic receptorProteinunknown
antagonist
HumanP18825 details
Alpha-2A adrenergic receptorProteinunknownNot AvailableHumanP08913 details
Related Articles
AbsorptionLurasidone is readily absorbed and quickly reaches maximal concentrations (Cmax) within 1-4 hours. When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours. This occurs regardless of fat or caloric content. Bioavailability = 9-19%.
Volume of distribution

6173 L

Protein binding~99% bound to serum proteins.
Metabolism

Lurasidone is metabolized by CYP3A4 in which its major active metabolite is referred to as ID-14283 (25% of parent exposure). Its two minor metabolites are referred to as ID14326 and ID11614 which make up 3% and 1% of parent exposure respectively. Its two non-active metabolites are referred to as ID-20219 and ID-20220.

SubstrateEnzymesProduct
Lurasidone
Not Available
ID11614Details
Lurasidone
Not Available
ID14326Details
Route of eliminationUrine (~9%) and feces (~80%)
Half life40 mg dose= 18 hours 120 mg - 160 mg dose = 29-37 hours
Clearance

3902 mL/min

ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Lurasidone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineLurasidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineLurasidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineLurasidone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineLurasidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Lurasidone.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Lurasidone.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Lurasidone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Lurasidone.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lurasidone.Withdrawn
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Lurasidone.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Lurasidone.Approved, Investigational
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Lurasidone.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Lurasidone.Approved, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Lurasidone.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Lurasidone.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Lurasidone.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lurasidone.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Lurasidone.Approved
AmiodaroneThe serum concentration of Lurasidone can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Lurasidone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amperozide.Experimental
AmphetamineLurasidone may decrease the stimulatory activities of Amphetamine.Approved, Illicit
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Lurasidone.Approved, Investigational
AprepitantThe serum concentration of Lurasidone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Lurasidone.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Lurasidone.Approved
AtazanavirThe serum concentration of Lurasidone can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Lurasidone can be increased when it is combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Azaperone.Vet Approved
AzelastineLurasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Lurasidone is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Lurasidone.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Lurasidone.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Lurasidone.Approved
BenzphetamineLurasidone may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Lurasidone.Approved
BexaroteneThe serum concentration of Lurasidone can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe serum concentration of Lurasidone can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Lurasidone can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Lurasidone can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Lurasidone.Approved, Illicit
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Lurasidone.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brotizolam.Approved, Withdrawn
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Lurasidone.Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Lurasidone.Approved, Investigational
BuprenorphineLurasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Lurasidone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Lurasidone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Lurasidone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Lurasidone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Lurasidone.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lurasidone.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lurasidone.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone.Approved
CarbamazepineThe serum concentration of Lurasidone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Lurasidone.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Carisoprodol.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Lurasidone.Experimental
CeritinibThe serum concentration of Lurasidone can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Lurasidone.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lurasidone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Lurasidone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lurasidone.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorphenamine.Approved
ChlorphentermineLurasidone may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lurasidone.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lurasidone.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Lurasidone.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorzoxazone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Lurasidone.Experimental
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Lurasidone.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Lurasidone.Approved
ClarithromycinThe serum concentration of Lurasidone can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Lurasidone can be increased when it is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Lurasidone.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Lurasidone.Approved, Illicit
ClotrimazoleThe serum concentration of Lurasidone can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Lurasidone.Approved
CobicistatThe serum concentration of Lurasidone can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Lurasidone.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Lurasidone.Approved, Illicit
ConivaptanThe serum concentration of Lurasidone can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Lurasidone can be increased when it is combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lurasidone.Approved
CyclosporineThe serum concentration of Lurasidone can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Lurasidone can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Lurasidone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dapoxetine.Investigational
DarunavirThe serum concentration of Lurasidone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Lurasidone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Lurasidone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Lurasidone can be increased when it is combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Lurasidone.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Lurasidone.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lurasidone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Lurasidone.Approved
DetomidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Lurasidone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lurasidone.Approved, Vet Approved
DextroamphetamineLurasidone may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lurasidone.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Lurasidone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Lurasidone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Lurasidone.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Lurasidone.Approved, Illicit, Vet Approved
DiethylpropionLurasidone may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lurasidone.Approved, Illicit
DihydroergotamineThe serum concentration of Lurasidone can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Lurasidone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lurasidone.Experimental, Illicit
DiltiazemThe serum concentration of Lurasidone can be increased when it is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lurasidone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lurasidone.Approved, Illicit
DisopyramideLurasidone may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Lurasidone.Approved
DopamineDopamine may increase the hypotensive activities of Lurasidone.Approved
DoramectinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Doxepin.Approved
DoxycyclineThe serum concentration of Lurasidone can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Lurasidone is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved, Illicit
DronedaroneThe serum concentration of Lurasidone can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Lurasidone.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lurasidone.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Lurasidone.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Lurasidone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Lurasidone.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Lurasidone.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Lurasidone can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Lurasidone.Approved, Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lurasidone.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Lurasidone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Lurasidone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Lurasidone can be decreased when it is combined with Enzalutamide.Approved
EpinephrineEpinephrine may increase the hypotensive activities of Lurasidone.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lurasidone.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lurasidone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Lurasidone.Approved
ErythromycinThe serum concentration of Lurasidone can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Lurasidone.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Lurasidone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Lurasidone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lurasidone.Approved
EthanolLurasidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lurasidone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Lurasidone.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Lurasidone.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Lurasidone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Lurasidone.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Lurasidone.Illicit, Vet Approved
EtravirineThe serum concentration of Lurasidone can be decreased when it is combined with Etravirine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Lurasidone.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Lurasidone.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Lurasidone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fexofenadine.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Lurasidone.Approved
FluconazoleThe serum concentration of Lurasidone can be increased when it is combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Lurasidone.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Lurasidone.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Lurasidone.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Lurasidone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Lurasidone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Lurasidone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Lurasidone.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fluticasone Propionate.Approved
FluvoxamineThe serum concentration of Lurasidone can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Lurasidone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Lurasidone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Lurasidone can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Lurasidone.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Lurasidone.Approved, Investigational
Fusidic AcidThe serum concentration of Lurasidone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Lurasidone.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Lurasidone is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Lurasidone.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Lurasidone is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Lurasidone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Lurasidone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Lurasidone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Lurasidone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Lurasidone.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Lurasidone.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Lurasidone.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Lurasidone.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Lurasidone.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lurasidone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Lurasidone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Lurasidone.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Lurasidone.Approved
HydrocodoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Lurasidone.Approved, Illicit
Hydroxyamphetamine hydrobromideLurasidone may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
IdelalisibThe serum concentration of Lurasidone can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Iloperidone.Approved
ImatinibThe serum concentration of Lurasidone can be increased when it is combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Lurasidone can be increased when it is combined with Indinavir.Approved
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Lurasidone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Lurasidone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Lurasidone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Lurasidone.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lurasidone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lurasidone.Approved
IsavuconazoniumThe serum concentration of Lurasidone can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Lurasidone.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Lurasidone.Approved, Vet Approved
IsradipineThe serum concentration of Lurasidone can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Lurasidone can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Lurasidone can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Lurasidone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Lurasidone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Lurasidone.Approved
KetoconazoleThe serum concentration of Lurasidone can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Lurasidone.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Lurasidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Lurasidone.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Lurasidone.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Lurasidone.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Lurasidone.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Lurasidone.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Lurasidone.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Lurasidone.Approved
LisdexamfetamineLurasidone may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Lurasidone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lurasidone is combined with Lofentanil.Illicit
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Lurasidone.Approved
LopinavirThe serum concentration of Lurasidone can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Lurasidone.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Lurasidone.Approved
LovastatinThe serum concentration of Lurasidone can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Lurasidone.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Lurasidone.Investigational
LuliconazoleThe serum concentration of Lurasidone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Lurasidone can be decreased when it is combined with Lumacaftor.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Lurasidone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Melperone.Approved
MephedroneLurasidone may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineLurasidone may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lurasidone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lurasidone.Approved, Illicit
MequitazineLurasidone may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Lurasidone.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Metaxalone.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Lurasidone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Lurasidone.Approved, Illicit
MethamphetamineLurasidone may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Lurasidone.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Lurasidone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Lurasidone.Approved
MethotrimeprazineLurasidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Lurasidone.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Lurasidone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Lurasidone.Approved, Investigational
MetyrosineLurasidone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Lurasidone.Approved, Illicit
MifepristoneThe serum concentration of Lurasidone can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Lurasidone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Lurasidone.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Lurasidone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved, Investigational
MirtazapineLurasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Lurasidone.Approved, Investigational
MitotaneThe serum concentration of Lurasidone can be decreased when it is combined with Mitotane.Approved
MMDALurasidone may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Lurasidone.Approved
ModafinilThe serum concentration of Lurasidone can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Lurasidone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Lurasidone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved, Investigational
NafcillinThe serum concentration of Lurasidone can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Lurasidone.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Lurasidone.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Lurasidone.Approved, Investigational
NefazodoneThe serum concentration of Lurasidone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Lurasidone can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Lurasidone can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Lurasidone can be decreased when it is combined with Nevirapine.Approved
NilotinibThe serum concentration of Lurasidone can be increased when it is combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Lurasidone.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Lurasidone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Lurasidone.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lurasidone.Approved, Investigational
OlaparibThe serum concentration of Lurasidone can be increased when it is combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Lurasidone.Approved
OpiumThe risk or severity of adverse effects can be increased when Lurasidone is combined with Opium.Approved, Illicit
OrphenadrineLurasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Lurasidone.Investigational
OsimertinibThe serum concentration of Lurasidone can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lurasidone.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Lurasidone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Lurasidone.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Lurasidone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Lurasidone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Lurasidone can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Lurasidone.Approved
ParaldehydeLurasidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Lurasidone.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Lurasidone.Approved, Vet Approved
PentobarbitalThe serum concentration of Lurasidone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
PerazineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Lurasidone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Lurasidone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Lurasidone.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Lurasidone.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Lurasidone.Approved, Withdrawn
PhenobarbitalThe serum concentration of Lurasidone can be decreased when it is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Lurasidone is combined with Phenoxyethanol.Approved
PhentermineLurasidone may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe serum concentration of Lurasidone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Lurasidone.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lurasidone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Lurasidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Lurasidone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleLurasidone may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Lurasidone.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Lurasidone.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Lurasidone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Lurasidone.Approved
PrimidoneThe serum concentration of Lurasidone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideLurasidone may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Lurasidone.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Lurasidone.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lurasidone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Lurasidone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Lurasidone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Lurasidone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Lurasidone.Investigational
PseudoephedrineLurasidone may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Lurasidone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lurasidone.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Lurasidone.Approved
QuinidineLurasidone may increase the QTc-prolonging activities of Quinidine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Lurasidone can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lurasidone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lurasidone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Lurasidone.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Lurasidone.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Lurasidone.Approved
RifabutinThe serum concentration of Lurasidone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Lurasidone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Lurasidone can be decreased when it is combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Lurasidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ritanserin.Investigational
RitobegronLurasidone may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe serum concentration of Lurasidone can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Lurasidone.Approved
RomifidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Romifidine.Vet Approved
RopiniroleLurasidone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Lurasidone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lurasidone.Approved, Investigational
RotigotineLurasidone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Lurasidone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Lurasidone.Experimental
Sage 547The risk or severity of adverse effects can be increased when Lurasidone is combined with Sage 547.Investigational
SaquinavirThe serum concentration of Lurasidone can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Lurasidone.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lurasidone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Lurasidone.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Lurasidone.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Lurasidone.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lurasidone.Approved, Vet Approved
SildenafilThe serum concentration of Lurasidone can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Lurasidone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Lurasidone can be increased when it is combined with Simeprevir.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Lurasidone.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
St. John's WortThe serum concentration of Lurasidone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Lurasidone can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lurasidone.Approved, Investigational
SulfisoxazoleThe serum concentration of Lurasidone can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Lurasidone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Lurasidone.Approved, Investigational
SuvorexantLurasidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Lurasidone.Approved
TelaprevirThe serum concentration of Lurasidone can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Lurasidone can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Lurasidone.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lurasidone.Approved
TetracaineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Lurasidone.Investigational
ThalidomideLurasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Lurasidone.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Lurasidone.Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Lurasidone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Lurasidone.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Lurasidone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tiapride.Investigational
TiclopidineThe serum concentration of Lurasidone can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Lurasidone can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Lurasidone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lurasidone.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Lurasidone is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Lurasidone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Lurasidone.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lurasidone.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Lurasidone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Lurasidone.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lurasidone.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Lurasidone.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Triprolidine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Lurasidone.Withdrawn
Uc1010The risk or severity of adverse effects can be increased when Lurasidone is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Lurasidone.Approved, Investigational
VenlafaxineThe serum concentration of Lurasidone can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Lurasidone can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Lurasidone is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Lurasidone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lurasidone.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Lurasidone.Approved, Investigational
VoriconazoleThe serum concentration of Lurasidone can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lurasidone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Lurasidone can be increased when it is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lurasidone.Approved, Investigational
ZolpidemLurasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Lurasidone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lurasidone.Approved, Investigational
Food Interactions
  • When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours.
References
Synthesis ReferenceNot Available
General References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
  2. Tarazi FI, Stahl SM: Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. [PubMed:22849428 ]
External Links
ATC CodesN05AE05
AHFS Codes
  • 28:16.08.04
PDB EntriesNot Available
FDA labelDownload (452 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9907
Caco-2 permeable+0.5257
P-glycoprotein substrateSubstrate0.6029
P-glycoprotein inhibitor IInhibitor0.6713
P-glycoprotein inhibitor IIInhibitor0.73
Renal organic cation transporterInhibitor0.5487
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5922
CYP450 1A2 substrateNon-inhibitor0.677
CYP450 2C9 inhibitorInhibitor0.6714
CYP450 2D6 inhibitorNon-inhibitor0.8292
CYP450 2C19 inhibitorInhibitor0.7439
CYP450 3A4 inhibitorNon-inhibitor0.7835
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8126
Ames testNon AMES toxic0.6477
CarcinogenicityNon-carcinogens0.8986
BiodegradationNot ready biodegradable0.9959
Rat acute toxicity2.4051 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6636
hERG inhibition (predictor II)Inhibitor0.5858
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral120 mg
TabletOral20 mg
TabletOral40 mg
TabletOral60 mg
TabletOral80 mg
Tablet, film coatedOral120 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral60 mg/1
Tablet, film coatedOral80 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5532372 No1998-07-022018-07-02Us
US8729085 No2006-05-262026-05-26Us
US8883794 No2006-05-262026-05-26Us
US9174975 No2006-06-252026-06-25Us
US9259423 No2011-05-232031-05-23Us
USRE45573 No2005-06-232025-06-23Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00789 mg/mLALOGPS
logP5.25ALOGPS
logP4.56ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)8.5ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area56.75 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity139.33 m3·mol-1ChemAxon
Polarizability56.2 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Norbornane monoterpenoid
  • Monoterpenoid
  • Isoindolone
  • Aromatic monoterpenoid
  • Isoindole or derivatives
  • Isoindoline
  • 1,2-benzothiazole
  • Dialkylarylamine
  • N-alkylpiperazine
  • Dicarboximide
  • Imidolactam
  • Benzenoid
  • N-alkylpyrrolidine
  • 2-pyrrolidone
  • Pyrrolidone
  • Carboxylic acid imide, n-substituted
  • Heteroaromatic compound
  • Thiazole
  • Pyrrolidine
  • Carboxylic acid imide
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Tarazi FI, Stahl SM: Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. [PubMed:22849428 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936 ]
Comments
comments powered by Disqus
Drug created on July 24, 2011 11:04 / Updated on December 04, 2016 03:20